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Background: Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. Despite the
widespread availability of evidence-based clinical guidelines and validated risk predication equations for prevention
and management of CVD, their translation into routine practice is limited. We developed a multifaceted quality
improvement intervention for CVD risk management which incorporates electronic decision support, patient risk
communication tools, computerised audit and feedback tools, and monthly, peer-ranked performance feedback via
a web portal. The intervention was implemented in a cluster randomised controlled trial in 60 primary healthcare
services in Australia. Overall, there were improvements in risk factor recording and in prescribing of recommended
treatments among under-treated individuals, but it is unclear how this intervention was used in practice and what
factors promoted or hindered its use. This information is necessary to optimise intervention impact and maximally
implement it in a post-trial context. In this study protocol, we outline our methods to conduct a theory-based,
process evaluation of the intervention. Our aims are to understand how, why, and for whom the intervention
produced the observed outcomes and to develop effective strategies for translation and dissemination.
Methods/Design: We will conduct four discrete but inter-related studies taking a mixed methods approach. Our
quantitative studies will examine (1) the longer term effectiveness of the intervention post-trial, (2) patient and
health service level correlates with trial outcomes, and (3) the health economic impact of implementing the
intervention at scale. The qualitative studies will (1) identify healthcare provider perspectives on implementation
barriers and enablers and (2) use video ethnography and patient semi-structured interviews to understand how
cardiovascular risk is communicated in the doctor/patient interaction both with and without the use of intervention.
We will also assess the costs of implementing the intervention in Australian primary healthcare settings which will
inform scale-up considerations.
Discussion: This mixed methods evaluation will provide a detailed understanding of the process of implementing
a quality improvement intervention and identify the factors that might influence scalability and sustainability.
Trials registration: 12611000478910.
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Cardiovascular disease burden
Non-communicable diseases (NCDs)? including cardio-
vascular diseases (CVD), cancers, respiratory diseases, and
diabetes mellitus? are the leading cause of death world-
wide [1,2]. It is predicted that by 2030, NCDs will account
for 75% of all deaths with the largest proportion of deaths
attributed to CVD [3]. Globally, approximately 17 million
(30%) deaths per year and 151 million disability-adjusted
life years (DALYs) are caused by CVD [4].
In Australia, CVD is responsible for 34% of deaths
and 18% of the burden of disease and injury, making it
the largest contributor to health system expenditure
[5]. Aboriginal and Torres Strait Islander people experi-
ence a greater CVD burden than other Australians, and
this is a major contributing factor to the 10-year gap in
life expectancy [6,7]. The majority of CVD is caused by
modifiable risk factors, which include blood pressure,
lipids, diabetes, body mass index (BMI), tobacco smok-
ing, alcohol use, unhealthy diet, physical inactivity, and
psychosocial stress [8]. Recent modelling suggests that
a 25% reduction in the prevalence of six NCD risk fac-
tors alone (tobacco, alcohol, salt, blood pressure, obes-
ity, and glucose) could reduce global disease burden by
25% in the next 10 years [9].
Evidence practice gaps
International clinical guidelines recommend that assess-
ment for CVD prevention and management should be
based on a combination of risk factors (the ? absolute risk ?
approach) rather than treating risk factors such as ele-
vated blood pressure and cholesterol in isolation [10-13].
Absolute risk calculation estimates an individual ? s risk
of a CVD event over time based on modifiable and
non-modifiable risk factors such as age and gender. This
enables early identification, management, and primary
prevention of CVD for individuals at high risk. In combin-
ation with well-established secondary prevention recom-
mendations for people who have experienced a previous
CVD event, the absolute risk approach offers considerable
potential for reducing CVD burden [14].
Despite the widespread availability and consistency of
these guidelines and the availability of validated risk pre-
diction equations, there are large evidence practice gaps.
Health professionals tend to use these guidelines and
equations sporadically and inconsistently [15,16]. In the
Australian context, studies have found that only 50% of
adults attending primary healthcare have been screened
for CVD risk in accordance with guideline recommenda-
tions, and only 40% of those identified as high risk have
been prescribed recommended medications [17,18]. In-
ternational studies have similarly demonstrated that a
minority of people are being provided with appropriate
screening measures and preventive treatments [19]. Themajority of CVD events can potentially be averted with
adequate implementation of established treatments and
interventions that are effective, efficient, and universally
accessible in Australian primary healthcare settings.
Primary healthcare is the ? front-line ? for effective pre-
vention and management of the increasing burden of
chronic diseases. With 88% of Australians visiting a gen-
eral practitioner each year, the opportunities to improve
primary and secondary prevention of CVD at this level are
great [20].
Knowledge translation strategies
Given the magnitude of these evidence practice gaps in
CVD prevention, effective quality improvement (QI) in-
novations that support health services to improve their
outcomes are urgently needed. QI is a multidimensional
concept that focuses on improving the efficiency and
process of a program, service, or organisation, resulting
in improved health outcomes [21,22]. The Agency for
Healthcare Research and Quality (AHRQ) has identified
nine broad QI strategies to improve quality of care: pro-
vider reminder systems, facilitated relay of clinical data
to providers, audit and feedback, provider education, pa-
tient education, promotion of self-management, patient
reminder systems, organisational change, and financial
incentives, regulation, and policy [23]. An increasingly
important component of QI strategies is an adoption of
health information technologies (HITs). Meaningful use
of electronic health records (EHRs), computerised pro-
vider order entry systems, and electronic decision sup-
port (EDS) are increasingly recognised as key enablers to
improvements in quality and delivery of healthcare [24].
However, the overall impact of computerised QI inter-
ventions to improve CVD burden has been limited, and
effects on patient outcomes remain unclear [25-27].
Whilst QI strategies have been well characterised, there
is relatively little knowledge translation research to help
guide how these strategies can be optimally implemented
into routine practice [28,29]. The Canadian Institute of
Health Research defines knowledge translation as ? the ex-
change, synthesis and ethically sound application of know-
ledge? within a complex system of interactions among
researchers and users? to accelerate the capture of the
benefits of research for patients through improved health,
more effective services and products and a strengthened
health care system? [30]. Whilst it is critical that QI inter-
ventions are robustly assessed for effectiveness, equally
important is a detailed understanding of how those QI
interventions are implemented, using process and eco-
nomic evaluations. This will allow a deeper understand-
ing of how the intervention worked/did not work, in
which contexts was it most effective/ineffective, and why.
Given QI interventions are inevitably complex in nature,
robust evaluation requires the use of multiple theories and
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ledge translation frameworks, we are able to better iden-
tify active ingredients of the intervention that change
behaviour, causal mechanisms of change, effective modes
of delivery, and the intended population or target [31].
This will enable promotion and integration of the inter-
ventions into clinical practice, health systems, and policy.
The treatment of cardiovascular risk in primary care using
electronic decision support (TORPEDO) study
There have been few randomised evaluations of QI in-
terventions in the Australian primary healthcare setting.
We designed a multifaceted QI intervention for CVD
risk management in Australian primary healthcare. The
intervention drew on two established QI mechanisms:
1) electronic decision support and 2) audit and feedback
(summary of the clinical performance over a specified
period of time) [32-37]. The intervention was evaluated
in the TORPEDO study, a cluster-randomised controlledFigure 1 Real-time decision support interface.trial (cRCT) involving 60 health services. Details of the
trial are published elsewhere [38]. In brief, the system was
integrated with the healthcare provider ? s EHRs, and in-
cluded (1) a real-time decision support interface using an
algorithm derived from several evidence based national
guidelines (Figure 1); (2) a patient risk communication
interface which included ?what if scenarios? to show the
benefits from particular health risk factor improvement
during a consultation (Figure 2); (3) an automated clin-
ical audit tool for extraction of data and review of
health service performance (Figure 3); and (4) a web
portal where services can view peer-ranked perform-
ance over time (Figure 4). Healthcare providers could
use the point-of-care tool as part of a routine clinical
consultation. For the audit and feedback component,
quality indicators were developed for patients who had
visited the health service at least three times in the pre-
ceding 2 years and once in the preceding 6 months.
The population studied was based on national guideline
Figure 2 Patient-oriented risk communication interface.
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Aboriginal and Torres Strait Islander people over 35 years
and all others over 45 years [38].
Data were collected for 38,725 people from the 60
health services. Overall, when compared with control,
the intervention was associated with a 25% relative (10%
absolute) improvement in CVD risk factor screening.
Overall, there was no significant difference in the pre-
scribing rates of recommended medicines to people at
high CVD risk. The intervention was, however, strongly
associated with improvements in the sub-group at high
CVD risk that was not prescribed with recommended
medicines at baseline. There were also improvements
in intensification of existing, recommended medication
regimens. There were modest improvements in attain-
ing blood pressure targets but no differences in other
clinical outcomes. The improvements in recommendedprescriptions to high risk patients were not accompan-
ied by increased prescribing rates for patients at low
risk [39].
Although the intervention exhibited significant im-
provements in some outcomes, it remains unclear how
this intervention was actually used in practice and what
factors promoted and hindered its use. Answers to these
questions are critical in order to inform future directions
for its implementation and for implementation of similar
interventions in other settings.
In this paper, we outline our protocol for a theory-
based process evaluation of the TORPEDO intervention.
The broad objectives are to understand how, why, and
for whom the intervention produced the observed out-
comes and to develop effective strategies for translation
and dissemination. The evaluation will identify which in-
tervention components promoted or had minimal impact
Figure 3 Automated data extraction tool? sample health service performance on CVD risk factor screening.
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chanism of change. It will also identify the contextual
influences on the delivery of the intervention and its
outcomes. The specific objectives are the following:
1. To understand whether intervention effects are
sustained in a post-trial setting;
2. To identify implementation barriers and enablers;
3. To understand how CVD risk is communicated in
the doctor/patient interaction both with and without
the use of the intervention; and
4. To identify cost considerations for delivering the
intervention at scale in the Australian primary
healthcare system.
Design and methods
Taking a mixed methods approach, we will conduct
four discrete but inter-related studies to address our study
objectives. Specifically, we will adopt an explanatorysequential design whereby the qualitative data analysis
will be used to gain a better understanding of the quan-
titative findings [40].
Logic model
Drawing on the RE-AIM framework, a logic model was
developed to assist in the planning, conduct, and evalu-
ation of the research components (Figure 5) [41-44].
The model assesses five dimensions of the intervention
at different levels (individual, health service/clinic or
organisation, and community/population): (1) partici-
pant Reach; (2) Effectiveness of the intervention; (3)
Adoption by the target health service; (4) Implementa-
tion fidelity, costs, and adaptations made during delivery;
and (5) Maintenance of intervention effects over time.
The model identifies and describes inputs, activities, out-
puts, and outcomes of the intervention [45]. The four ob-
jectives have been mapped onto the relevant components
of the RE-AIM framework.
Figure 4 Quality improvement portal.
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tical perspectives? realist evaluation [46], the theoretical
domain framework (TDF) [47,48], and normalisation
process theory (NPT) [49,50].
Realist evaluation
Realist evaluation seeks to answer the question what
works, for whom, and in what circumstances? [46]. This
is accomplished by identifying and understanding the
underlying mechanisms by which the intervention suc-
ceeds or fails in varying contexts to produce the patterns
of outcomes. Therefore, unpacking of the underlying
generative mechanisms of the intervention and its effects
is contingent on understanding the features of the con-
text (i.e. roles and relationships of personnel at health
services, IT infrastructure, economic conditions, demo-
graphic, motivation and skills of health professionals,
etc.) [46,51,52].Theoretical domain framework
Successful implementation of evidence-based guidelines
and QI interventions depends largely on changing the be-
haviour of healthcare professionals and patients, who are
influenced by external (i.e. organisational, environmental,
resources) and internal (i.e. motivation, capability) factors.
TDF is a consensus of numerous behaviour change mo-
dels and comprises 14 domains derived from psycho-
logical and organisational theory (knowledge, skills, social/
professional role and identity, beliefs about capabilities,
optimism, beliefs about consequences, reinforcement, in-
tentions, goals, memory attention and decision process,
environmental context and resources, social influences,
emotion, and behavioural regulation) [47,48,53].
Normalisation process theory
In order for healthcare innovation and technology to be-
come routinely embedded in every day work, we need to
Figure 5 Logic model for TORPEDO process evaluation.
Patel et al. Implementation Science 2014, 9:187 Page 7 of 12
http://www.implementationscience.com/content/9/1/187understand how the innovation is integrated within the
existing practices of a healthcare organisation. NPT assists
in understanding how health professionals implement an
intervention. NPT identified four main components: (1)
coherence (sense making by participants), (2) cognitive
participation (commitment and engagement by partici-
pants), (3) collective action (the work participants do to
make the intervention function), and (4) reflexive moni-
toring (the degree to which participants reflect on or ap-
praise the intervention [49,54,55].
Study 1: Post-trial effectiveness of the intervention
(objective 1)
Aim
To assess the effects of the intervention at one year fol-
lowing completion of the cRCT.
Methods
At the end of study follow-up visit for the TORPEDO
study, all 60 health services have the option to either
continue the use of the intervention or have the interven-
tion implemented for use in the usual care health servicesfor an additional 12 months. A post-trial clinical audit
data extraction at minimum of 24 months from baseline
will be conducted for the health services expressing inter-
est to use the intervention. The objective of this study is
to assess the impact of the use of the intervention over
time on the two primary outcomes: (1) proportion of
CVD risk factor screening and (2) proportion of appropri-
ate medication prescription in the high risk individuals for
the intervention arm and usual care arm at post-end of
study following baseline.Analysis
Log-binomial regression will allow direct estimation of
risks and risk ratios (i.e. relative risks) on each outcome.
The model will be adjusted with intervention (yes vs.
no) and time (baseline, 12 and 24 month) as categorical
data where baseline is set as reference and interaction
between intervention and time. The model will be ad-
justed with the intervention (yes or no) and with a ran-
dom centre effect. Chi-square test and 95% confidence
intervals (CI) will be computed.
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Aim
To determine what patient and health service level vari-
ables correlate with the trial outcomes.
Methods
Patient variables (age, gender, ethnicity, history of CVD,
and diabetes) will be obtained from the automated clin-
ical audit tool, and health service level variables will be
collected through Team Climate Inventory (TCI) and
Warr-Cook-Wall job satisfaction surveys, customised for
use with general practices (GPs) and Aboriginal Com-
munity Controlled Health Services (ACCHSs), adminis-
tered to all general practitioners and other practice and
health service staff at the participating 60 sites [56,57].
In addition, health service characteristics such as service
size, participation in quality improvement programs, and
type of primary healthcare (GP verses ACCHS) will be
collected at randomisation.
Analysis
TCI is a 44-item questionnaire, and items are rated on a
5-point scale [56]. Job satisfaction is a 15-item question-
naire, and items are rated on a 7-point scale [57]. Multi-
level regression model analysis will be conducted to
evaluate the influence of team climate and job satisfaction
on the primary study outcomes, controlling for patient? s
age, gender, practice size, type of PHC, and participation
in quality improvement programs. The results will be
interpreted within the context of the three conceptual per-
spectives to better understand what health service factors
(if any) are important drivers of use of the intervention in
routine practice.
Study 3: Interview study and video ethnography
(objectives 2 and 3)
Aim
To identify and understand which intervention compo-
nents promoted or had minimal impact on behaviour
change at the provider and patient levels, the mechanism
of change, and contextual influences.
Methods
Case study methods will be used to explore system chan-
ges over time, through in-depth qualitative data collection
involving multiple sources of information. The cases will
be individual GPs and ACCHSs participating in the
TORPEDO study. Quantitative data obtained from the
primary study and the studies 1 and 2 above will be
drawn on as part of the analysis of the cases, and new
qualitative data will be obtained using semi-structured
interviews, video ethnography, and surveys. This will
ensure that both intervention effects and implemen-
tation processes are comprehensively assessed. It willidentify contextual influences, and by drawing on mul-
tiple empirical data sources will increase the robustness
of the findings [58,59].
We will purposively sample health services to achieve
maximum variation in trial primary outcomes, numbers
of staff at each site, and type of service (GP versus ACCHS,
urban versus rural). We will select six cases from the inter-
vention arm (four GPs and two ACCHSs) and three cases
from the usual care arm (two GPs + one ACCHSs). There
will be two methods of data collection.Health professional interviews
Semi-structured interviews with site staff will provide us
with their knowledge, views, and experience of the im-
plementation of the intervention at their health service.
Interview questions have been developed to explore the
realist evaluation domains of context, mechanism, and
outcome. Some questions include the following: (1)
why health staff did/did not use the intervention; (2)
how was the intervention used in routine practice and
by whom; (3) what were the contextual factors that in-
fluenced its uptake; and (4) what impact did it have on
the way personnel did their work. We will conduct ap-
proximately 20 health professional interviews with ge-
neral practitioners, nurses, managers, Aboriginal health
workers (AHWs), and administrative assistants from
within our cases. The final number of interviews will be
dependent on thematic saturation [60]. The interviews
will take place at the health service, and all interviews will
be audio-recorded and transcribed. The interviews will
take place face to face with a thematic and topic-centred
interview guide. The interview guide will be flexible to
allow exploration of emergent themes.Video ethnography
Qualitative data obtained from ethnographic studies
can enhance our understanding of how to introduce a
technological innovation into healthcare [61,62]. In
order to augment our interview data, video ethnogra-
phy will be used to give us insight into (1) the possible
ways general practitioners used the intervention tools;
(2) how cardiovascular risk is talked about between
general practitioner and patient; (3) how patients receive
and interpret this information; and (4) what impact the
intervention tools have on the decision-making process,
particularly related to recommending and taking medica-
tion. Approximately 20% of patients video-recorded (ap-
proximately two per general practitioner) will be selected
to be interviewed after videotaping of their consultation.
Patients agreeing to participate will be interviewed at their
home or the health service at a time suitable for the
patient.
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Framework analysis will be used to organise the inter-
view data [63]. Key issues and emergent themes will be
identified and then a coding framework will be devel-
oped to index and chart interview transcripts and videos.
Videos will be subject to fine-grain discourse analysis
[64]. NVivo 10 software (QSR International) will be used
for data management and coding of interview tran-
scripts, field notes, and videos. The analysis will occur
simultaneously with data collection. Themes will be devel-
oped both deductively (pre-defined themes) and induct-
ively (emerging themes), and then coded in an iterative
process to identify patterns, and interpret the meaning
of the themes within and across cases. Throughout this
process, we will meet regularly with a project working
group of expert researchers and collaborators to discuss
the theoretical framework within which the data will be
collected, coded, and interpreted. Reflexivity will be in-
corporated into the qualitative analysis process to take
into account personal assumptions and biases, so these
do not influence the way and the type of data that are
collected or the data analysed.
Our three chosen theoretical perspectives will be re-
gularly drawn on to assist with interpretation of the
qualitative findings. Using realist evaluation, we expect
the analysis to yield insights into particular context-
mechanism-outcome configurations that explain patterns
associated with use and non-use of the intervention. The
TDF will complement these analyses and explore to
what extent the intervention influenced behaviour change
by various actors (health professionals, managers, and
patients). Data will be used to make an assessment of
the underlying capacity, motivation, and opportunities
of these actors and the extent to which the intervention
influenced these areas. NPT will be used to provide a
better understanding of the ways in which health ser-
vices as organisational structures respond to the inter-
vention. Interview codes will be aligned with the four
NPT domains of coherence, cognitive participation, col-
lective action, and reflexive monitoring, and it is expected
this will facilitate our analyses and derivation of the key
messages.
Study 4: Cost consideration of scale-up (objective 4)
Aim
The cost implications for health services to adopt the
intervention, and deliver at scale in Australia.
Summary
A business model will be developed for health services
to adopt and maintain the intervention. We will both
quantitatively and qualitatively explore the factors that
will influence costs for the various types of health services
(i.e. large, medium and small health services, patient load/GP, etc.), capacity constraints within individual practices,
the investment needed to adopt the intervention, and the
potential returns to the practice in terms of patient care.
These will be assessed across a diverse range of practices.
This evidence will be obtained through clinical audit
data, surveys, and health professional semi-structured
interviews. The findings will be used to determine the
economic viability of the widespread adoption and im-
plementation of this intervention and inform policy by
ascertaining the support that individual practices will
need to accomplish these tasks and ultimately the costs
to government of scaling up.
Ethical considerations
The study is approved by The University of Sydney
Human Research Ethics Committee (2012/2183) and
the Aboriginal Health & Medical Research Council
(AH&MRC) of New South Wales (778/11). Participa-
tion agreements were signed between the participating
health services and the coordinating research institute.
De-identified patient level data is being extracted from
health service software systems to analyse post-trial
outcomes (study 1) and assess health service utilisation
costs (study 4). Participants in the TCI and job satisfaction
surveys (study 2) and the qualitative study components
will be provided with an information sheet and asked to
provide written informed consent to participate. Partici-
pants will be reassured of the confidential nature of any
data collected, and they will be identified by a unique
identification number only. Participants will be reminded
that they can opt not to answer any questions or can stop
interviews or videotaping at any time, and they will have a
right to withdraw consent and cease involvement in the
study without penalty.
Trial status
Data collection is underway. Preliminary qualitative data
analysis is being conducted contemporaneously with data
collection. Quantitative data analysis has not commenced.
Discussion
Addressing the challenges of CVD burden requires im-
plementation strategies for increasing the uptake of well-
established evidence into practice. Our attempt to address
this with a multifaceted QI intervention was moderately
but not uniformly successful, suggesting the need for a
rigorous process evaluation to understand how and in
what ways it was taken up in practice. Such evaluations
are crucial to understanding how implementation strat-
egies should be applied in non-trial settings.
Multifaceted interventions, by their nature, invariably
lead to complex usage patterns which can make inter-
pretation of study outcomes difficult. In order to maxi-
mise understanding that is relevant to other settings,
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our process evaluation is its multicomponent, multi-
theory approach combining diverse study designs to
make sense of how this particular knowledge translation
strategy was adopted into practice. Further, by examining
implementation from multiple perspectives (provider,
patient, health services, and system) the findings are ex-
pected to provide both micro- and macro-system per-
spectives which will be of interest to policy makers and
implementers. There are two key limitations to our ap-
proach (1) the majority of the data collection will occur
toward the end of the trial and in the post-trial phase
and may miss critical insights gained from early phase
adoption processes; and (2) the study setting is limited
to Australian primary healthcare settings and therefore
may be only of relevance to health systems with similar
contexts, financing, workforce structures, and adoption
of electronic medical records.
Despite these caveats, the adoption and successful
implementation of computerised QI interventions and
strategies are the key challenges for healthcare systems
worldwide. In 2009, the US government passed the
Health Information Technology for Economic and Cli-
nical Health Act as a stimulus to promote and adopt
?meaningful use ? of information technologies. The Act
provided incentive payments to hospitals and individual
practices totalling $14 ? 27 billion to adopt EHRs within
3 years to avoid financial penalties. This unprecedented
investment is a reflection of the importance of informa-
tion technology adoption for health systems reform. In
Australia, the National E-Health Transition Authority
was established in 2010 with a government investment
of over $467 million to develop and implement e-health
systems nationally. Despite such large publicly funded
investments, there remains uncertainty around the fac-
tors that will promote successful adoption of compu-
terised QI strategies.
This mixed methods process evaluation, grounded in a
theoretical framework, will evaluate the impact of a com-
plex, multifaceted intervention and help us to understand
the knowledge translation considerations for use of com-
puterised QI interventions in clinical practice.
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